Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Buy these five stocks ahead of earnings before it’s too late, Bank of America says
Bank of America said this week there’s plenty of quality buying opportunities left in companies that haven’t yet reported their latest results.
Shares of conservative cable channel Newsmax soar another 100% after massive debut
Newsmax shares soared for a second day after their public debut, as the conservative news channel gains traction during President Donald Trump’s second term.
House Republicans unveil bill to avoid shutdown and they’re daring Democrats to oppose it
House Republicans unveiled a spending bill Saturday that would keep federal agencies funded through Sept. 30.